Neutral sphingomyelinase inhibition participates to the benefits of N-acetylcysteine treatment in post-myocardial infarction failing heart rats. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Journal of Molecular and Cellular Cardiology Année : 2007

Neutral sphingomyelinase inhibition participates to the benefits of N-acetylcysteine treatment in post-myocardial infarction failing heart rats.

Résumé

Deficiency in cellular thiol tripeptide glutathione (l-gamma glutamyl-cysteinyl-glycine) determines the severity of several chronic and inflammatory human diseases that may be relieved by oral treatment with the glutathione precursor N-acetylcysteine (NAC). Here, we showed that the left ventricle (LV) of human failing heart was depleted in total glutathione by 54%. Similarly, 2-month post-myocardial infarction (MI) rats, with established chronic heart failure (CHF), displayed deficiency in LV glutathione. One-month oral NAC treatment normalized LV glutathione, improved LV contractile function and lessened adverse LV remodelling in 3-month post-MI rats. Biochemical studies at two time-points of NAC treatment, 3 days and 1 month, showed that inhibition of the neutral sphingomyelinase (N-SMase), Bcl-2 depletion and caspase-3 activation, were key, early and lasting events associated with glutathione repletion. Attenuation of oxidative stress, downregulation of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and its TNF-R1 receptor were significant after 1-month NAC treatment. These data indicate that, besides glutathione deficiency, N-SMase activation is associated with post-MI CHF progression, and that blockade of N-SMase activation participates to post-infarction failing heart recovery achieved by NAC treatment. NAC treatment in post-MI rats is a way to disrupt the vicious sTNF-alpha/TNF-R1/N-SMase cycle.
Fichier principal
Vignette du fichier
Adamy_et_al_JMCC_Juin07.pdf (1.45 Mo) Télécharger le fichier
Loading...

Dates et versions

inserm-00158065 , version 1 (22-08-2007)

Identifiants

Citer

Christophe Adamy, Paul Mulder, Lara Khouzami, Nathalie Andrieu-Abadie, Nicole Defer, et al.. Neutral sphingomyelinase inhibition participates to the benefits of N-acetylcysteine treatment in post-myocardial infarction failing heart rats.: NAC treatment in post-MI failing heart rat. Journal of Molecular and Cellular Cardiology, 2007, 43 (3), pp.344-53. ⟨10.1016/j.yjmcc.2007.06.010⟩. ⟨inserm-00158065⟩
273 Consultations
478 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More